Quantcast

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q2 2013

October 28, 2013

Reportbuyer.com just published a new market research report: Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q2 2013.

London (PRWEB) October 28, 2013

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q2 2013” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q2 2013. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in-house deals database and primary and secondary research.

Scope

-Analysis of the market trends for the pharmaceutical industry in the global arena.

-Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

-Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

-Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

-Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

-Analysis of partnership and licensing deals based on clinical stage of development of products.

-Summary of the pharmaceutical deals globally in the last five quarters.

-Information on the top deals happened in the pharmaceutical industry.

-Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

-League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

-Enhance your decision making capability in a more rapid and time sensitive manner.

-Find out the major deal performing segments for investments in your industry.

-Evaluate the types of company divesting and acquiring assets and ways to raise capital in the market.

-Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the oil and gas industry.

-Identify growth segments and opportunities in each region within the industry.

-Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 11

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q2 2013 15

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q2 2013 15

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q2 2013 18

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q2 2013 19

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2013 20

2.4.1 Life Technologies Receives Shareholders Approval for Its Acquisition by Thermo Fisher Scientific for US$13.6 Billion 20

2.4.2 Valeant Pharma Completes Acquisition of Bausch & Lomb for US$ 8.7 Billion 22

2.4.3 Actavis Receives French Competition Authority Approval to Acquire Warner Chilcott for US$8.5 Billion 23

2.4.4 Merck Completes Public Offering of Notes for US$6.5 Billion 24

2.4.5 Tenet Healthcare to Acquire Vanguard Health Systems for US$4.3 Billion 25

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 26

3.1 Pharmaceuticals & Healthcare, Global, M&A, Q2 2013 26

3.1.1 Top M&A Deals in Q2 2013 28

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q2 2012 – Q2 2013 29

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q2 2013 31

3.2.1 Top Initial Public Offerings in Q2 2013 32

3.2.2 Top Secondary Offerings in Q2 2013 32

3.2.3 Top PIPE Deals in Q2 2013 33

3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q2 2012-Q2 2013 33

3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q2 2012 – Q2 2013 34

3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q2 2013 36

3.3.1 Top Venture Financing Deals in Q2 2013 37

3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2013 38

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2013 39

3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q2 2012 – Q2 2013 40

3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 42

3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 44

3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q2 2013 45

3.4.1 Top Private Equity Deals in Q2 2013 46

3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q2 2012 – Q2 2013 47

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2013 49

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2013 49

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q2 2012 – Q2 2013 51

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2013 53

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q2 2013 54

4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2013 55

4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q2 2013 56

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 – Q2 2013 57

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q2 2012 – Q2 2013 59

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q2 2012 – Q2 2013 60

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 – Q2 2013 62

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q2 2013 64

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2013 64

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 – Q2 2013 66

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q2 2013 68

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q2 2013 68

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q2 2013 69

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q2 2012 – Q2 2013 70

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q2 2012 – Q2 2013 72

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2012 – Q2 2013 74

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2012 – Q2 2013 75

5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q2 2012 – Q2 2013 77

6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 79

6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q2 2012 – Q2 2013 79

6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q2 2012 – Q2 2013 81

6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2012 – Q2 2013 83

6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q2 2012 – Q2 2013 85

6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q2 2012 – Q2 2013 87

6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q2 2012 – Q2 2013 89

6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2012 – Q2 2013 90

7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 92

7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q2 2013 92

7.1.1 Oncology – Deals of the Quarter 94

7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q2 2013 96

7.2.1 Central Nervous System – Deals of the Quarter 98

7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q2 2013 99

7.3.1 Infectious Disease – Deals of the Quarter 101

7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q2 2013 103

7.4.1 Immunology – Deals of the Quarter 105

7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q2 2013 106

7.5.1 Metabolic Disorders – Deals of the Quarter 108

7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q2 2013 110

7.6.1 Cardiovascular – Deals of the Quarter 112

7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q2 2013 114

7.7.1 Gastrointestinal – Deals of the Quarter 116

7.8 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q2 2013 117

7.8.1 Ophthalmology – Deals of the Quarter 119

7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q2 2013 120

7.9.1 Respiratory – Deals of the Quarter 122

7.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q2 2013 124

7.10.1 Dermatology – Deals of the Quarter 126

8 Deal Summary by Geography 127

8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q2 2013 127

8.1.1 North America – Deals of the Quarter 129

8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q2 2013 132

8.2.1 Europe – Deals of the Quarter 134

8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q2 2013 136

8.3.1 Asia-Pacific – Deals of the Quarter 138

8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q2 2013 139

8.4.1 Rest of the World – Deals of the Quarter 141

9 Pharmaceuticals & Healthcare, Global, Top Advisors 143

9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 143

9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 145

10 Appendix 147

11 Further Information 151

11.1 Methodology 151

11.2 About GlobalData 152

11.3 Disclosure information 153

11.4 Disclaimer 153

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q2 2012 – Q2 2013 17

Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q2 2013 19

Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2013 20

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 27

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q2 2013 28

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q2 2012 – Q2 2013 30

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2012 – Q2 2013 32

Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q2 2013 32

Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q2 2013 32

Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q2 2013 33

Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q2 2012-Q2 2013 33

Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2012 – Q2 2013 35

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 37

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q2 2013 37

Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q2 2013 39

Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2012 – Q2 2013 41

Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2012 – Q2 2013 43

Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2012 – Q2 2013 44

Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 46

Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q2 2013 46

Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2012 – Q2 2013 48

Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 50

Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 52

Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 – Q2 2013 54

Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2013 54

Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2013 55

Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q2 2013 56

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2012 – Q2 2013 58

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2012 – Q2 2013 61

Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2012 – Q2 2013 63

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 65

Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 – Q2 2013 67

Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q2 2013 68

Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q2 2013 68

Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q2 2013 69

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 71

Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q2 2012 – Q2 2013 73

Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2012 – Q2 2013 76

Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2012 – Q2 2013 78

Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q2 2012 – Q2 2013 80

Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q2 2012 – Q2 2013 82

Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2012 – Q2 2013 84

Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q2 2012 – Q2 2013 86

Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q2 2012 – Q2 2013 88

Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q2 2012 – Q2 2013 89

Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2012 – Q2 2013 91

Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 93

Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 97

Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 100

Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 104

Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 107

Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 111

Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 115

Table 54: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 118

Table 55: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 121

Table 56: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 125

Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 128

Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 133

Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 137

Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 140

Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2012 – Q2 2013 144

Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2012 – Q2 2013 146

Table 63: Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q2 2012-Q2 2013 147

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q2 2012 – Q2 2013 15

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q2 2013 18

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q2 2013 19

Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q2 2012 – Q2 2013 26

Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q2 2012 – Q2 2013 29

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 31

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q2 2012 – Q2 2013 34

Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 36

Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q2 2013 38

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q2 2013 39

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2012 – Q2 2013 40

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2012 – Q2 2013 42

Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 45

Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2012 – Q2 2013 47

Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 49

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 51

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2012 – Q2 2013 53

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2012 – Q2 2013 57

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2012 – Q2 2013 59

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2012 – Q2 2013 60

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2012 – Q2 2013 62

Figure 22:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 64

Figure 23:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 – Q2 2013 66

Figure 24:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 70

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 – Q2 2013 72

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number of Deals, Q2 2012 – Q2 2013 74

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q2 2012 – Q2 2013 75

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 – Q2 2013 77

Figure 29:Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q2 2012 – Q2 2013 79

Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q2 2012 – Q2 2013 81

Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2012 – Q2 2013 83

Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q2 2012 – Q2 2013 85

Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q2 2012 – Q2 2013 87

Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q2 2012 – Q2 2013 89

Figure 35:Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2012 – Q2 2013 90

Figure 36: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 92

Figure 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 96

Figure 38: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 99

Figure 39: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 103

Figure 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 106

Figure 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 110

Figure 42: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 114

Figure 43: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 117

Figure 44: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 120

Figure 45: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 124

Figure 46: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 127

Figure 47: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 132

Figure 48: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 136

Figure 49: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q2 2012 – Q2 2013 139

Figure 50: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2012 – Q2 2013 143

Figure 51: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2012 – Q2 2013 145

Read the full report:

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q2 2013

http://www.reportbuyer.com/banking_finance/capital_markets/partnerships_licensing_investments_ma_deals_trends_pharmaceuticals_q2_2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Investment_Banking

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: http://www.reportbuyer.com/

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/10/prweb11274865.htm


Source: prweb



comments powered by Disqus